These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 29556418)

  • 21. Association of High Serum Interleukin-6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis.
    Boyapati A; Schwartzman S; Msihid J; Choy E; Genovese MC; Burmester GR; Lam G; Kimura T; Sadeh J; Weinreich DM; Yancopoulos GD; Graham NMH
    Arthritis Rheumatol; 2020 Sep; 72(9):1456-1466. PubMed ID: 32343882
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial.
    Strand V; Kosinski M; Chen CI; Joseph G; Rendas-Baum R; Graham NM; van Hoogstraten H; Bayliss M; Fan C; Huizinga T; Genovese MC
    Arthritis Res Ther; 2016 Sep; 18(1):198. PubMed ID: 27600829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sarilumab: Review of a Second IL-6 Receptor Antagonist Indicated for the Treatment of Rheumatoid Arthritis.
    Boyce EG; Rogan EL; Vyas D; Prasad N; Mai Y
    Ann Pharmacother; 2018 Aug; 52(8):780-791. PubMed ID: 29482351
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs.
    Muszbek N; Proudfoot C; Fournier M; Chen CI; Kuznik A; Kiss Z; Gal P; Michaud K
    Adv Ther; 2019 Jun; 36(6):1337-1357. PubMed ID: 31004324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study.
    Genovese MC; Fleischmann R; Kivitz AJ; Rell-Bakalarska M; Martincova R; Fiore S; Rohane P; van Hoogstraten H; Garg A; Fan C; van Adelsberg J; Weinstein SP; Graham NM; Stahl N; Yancopoulos GD; Huizinga TW; van der Heijde D
    Arthritis Rheumatol; 2015 Jun; 67(6):1424-37. PubMed ID: 25733246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sarilumab: A Review in Moderate to Severe Rheumatoid Arthritis.
    Lamb YN; Deeks ED
    Drugs; 2018 Jun; 78(9):929-940. PubMed ID: 29931592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis.
    Terpos E; Fragiadaki K; Konsta M; Bratengeier C; Papatheodorou A; Sfikakis PP
    Clin Exp Rheumatol; 2011; 29(6):921-5. PubMed ID: 22032557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential Binding of Sarilumab and Tocilizumab to IL-6Rα and Effects of Receptor Occupancy on Clinical Parameters.
    Xu C; Rafique A; Potocky T; Paccaly A; Nolain P; Lu Q; Iglesias-Rodriguez M; St John G; Nivens MC; Kanamaluru V; Fairhurst J; Ishii T; Maldonado R; Choy E; Emery P
    J Clin Pharmacol; 2021 May; 61(5):714-724. PubMed ID: 33314148
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone.
    Garnero P; Thompson E; Woodworth T; Smolen JS
    Arthritis Rheum; 2010 Jan; 62(1):33-43. PubMed ID: 20039425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN).
    Sieper J; Braun J; Kay J; Badalamenti S; Radin AR; Jiao L; Fiore S; Momtahen T; Yancopoulos GD; Stahl N; Inman RD
    Ann Rheum Dis; 2015 Jun; 74(6):1051-7. PubMed ID: 24550171
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data.
    Rehberg M; Giegerich C; Praestgaard A; van Hoogstraten H; Iglesias-Rodriguez M; Curtis JR; Gottenberg JE; Schwarting A; Castañeda S; Rubbert-Roth A; Choy EHS;
    Rheumatol Ther; 2021 Dec; 8(4):1661-1675. PubMed ID: 34519964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Periodontal Disease as a Risk Factor for Rheumatoid Arthritis: A Systematic Review.
    Kaur S; White S; Bartold M
    JBI Libr Syst Rev; 2012; 10(42 Suppl):1-12. PubMed ID: 27820156
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes.
    Genovese MC; van Adelsberg J; Fan C; Graham NMH; van Hoogstraten H; Parrino J; Mangan EK; Spindler A; Huizinga TWJ; van der Heijde D;
    Rheumatology (Oxford); 2018 Aug; 57(8):1423-1431. PubMed ID: 29746672
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A review of sarilumab for the treatment of rheumatoid arthritis.
    Lee EB
    Immunotherapy; 2018 Jan; 10(1):57-65. PubMed ID: 29043871
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522).
    Karsdal MA; Schett G; Emery P; Harari O; Byrjalsen I; Kenwright A; Bay-Jensen AC; Platt A
    Semin Arthritis Rheum; 2012 Oct; 42(2):131-9. PubMed ID: 22397953
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension.
    Burmester GR; Strand V; Rubbert-Roth A; Amital H; Raskina T; Gómez-Centeno A; Pena-Rossi C; Gervitz L; Thangavelu K; St John G; Boklage S; Genovese MC
    RMD Open; 2019; 5(2):e001017. PubMed ID: 31673415
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.
    Raimondo MG; Biggioggero M; Crotti C; Becciolini A; Favalli EG
    Drug Des Devel Ther; 2017; 11():1593-1603. PubMed ID: 28579757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of sarilumab as monotherapy and in combination with non-methotrexate disease-modifying anti-rheumatic drugs on unacceptable pain in patients with rheumatoid arthritis: a post-hoc analysis of the HARUKA phase 3 study.
    Tanaka Y; Takahashi T; van Hoogstraten H; Kato N; Kameda H
    Mod Rheumatol; 2024 Jul; ():. PubMed ID: 39073577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aliskiren, tadalafil, and cinnamaldehyde alleviate joint destruction biomarkers; MMP-3 and RANKL; in complete Freund's adjuvant arthritis model: Downregulation of IL-6/JAK2/STAT3 signaling pathway.
    Azouz AA; Saleh E; Abo-Saif AA
    Saudi Pharm J; 2020 Sep; 28(9):1101-1111. PubMed ID: 32922141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. UGT1A1 genetic variants are associated with increases in bilirubin levels in rheumatoid arthritis patients treated with sarilumab.
    Lin N; Damask A; Boyapati A; Hamilton JD; Hamon S; Ternes N; Nivens MC; Penn J; Lopez A; Reid JG; Overton J; Shuldiner AR; Abecasis G; Baras A; Paulding C
    Pharmacogenomics J; 2022 May; 22(3):160-165. PubMed ID: 35149777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.